Market reports & researches
LOG IN | Services | Contact | Custom Research



Main Healthcare, Pharmaceuticals & Biotechnology Healthcare and drugs Nucleic Acid Testing Markets in Taiwan
Publications

(Currently 512486 Items)


Partners


Healthcare and drugs / REPORT INFORMATION

Nucleic Acid Testing Markets in Taiwan

DateJun, 2006
Pages0
Price / format€4897 / Hard Copy
€4520 / Site License
€5650 / Enterprisewide

€4 483 

Report Information | Custom-Tailored Research | Product Trade Lead


Abstract:
 This Frost & Sullivan research service entitled Nucleic Acid Testing Markets in Taiwan gives an overview of the current status of the nucleic acid testing market in Taiwan and discusses present and potential revenues. The study also discusses the prevailing industry challenges and gives an overview of the reimbursement system and regulatory environment for NAT in Taiwan.

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

By Application:

- Polymerase Chain Reaction (PCR)

- RT-PCR

- Other Platforms

Technologies

The following technologies are covered in this research:

- Nucleic Acids: Various high molecular weight acids, such as DNA and RNA, found in all living cells as well as viruses and made up of nucleotide chains, which carry genetic information.
- Nucleic Acid Testing (NAT): Nucleic acid-based amplification test.
- Polymerase Chain Reaction (PCR): A revolutionary technology, which generates multiple copies of a specific nucleotide sequence from a target organism and able to detect trace elements of target organisms with high specificity. Applications include biological research, clinical diagnostics, forensics, and genetics.
- RT-PCR: Real-time measurement for PCR, through quantitative detection of specific nucleic acid sequences and permits accurate and informative measurements for DNA or RNA quantification. Real-time applications include measuring gene expression and detecting bacterial or viral load within samples.
- bDNA: Amplified detection of minute quantities of genetic material (DNA or RNA) and direct quantification of virus in serum or plasma. Distinct from PCR due to the measurement of the virus present through amplification of signals, rather than target sequences.
- Enzyme-linked Immunosorbent Assay (ELISA): Detection and measurement of an immune response in a solution. The presence of antigens or antibodies is verified and visualized with an application of tagged antibodies. It is generally less sensitive than nucleic acid-based amplification techniques.
- Ligase Chain Reaction (LCR): A technique for the detection of any defined DNA sequence by amplification of ligation products complementary to the target sequence. Similar to PCR, this method allows the detection of minute levels of known nucleic acid sequences.
- Nucleic Acid Sequence-based Amplification (NASBA): Alternative to PCR, whereby RNA or DNA is selectively amplified through continual amplification at a constant temperature.
- Strand Displacement Amplification (SDA): In contrast to other techniques, which rely on thermal cycling, SDA is an isothermal process (entire reaction is performed at a uniform temperature) that employs a series of primers, DNA polymerase, and a restriction enzyme to exponentially amplify the target nucleic acid sequence.
- Transcription Mediated Amplification (TMA): An isothermal RNA transcription amplification technique employing RNA polymerase and reverse transcriptase to drive the reaction. TMA can amplify either DNA or RNA, producing an RNA amplicon, in contrast to most other nucleic acid amplification methods that only produce DNA.
- Point-of-care Testing (POCT): Pathology investigation by or on behalf of the treating medical practitioner on-site. It is a diagnostic testing conducted close to the site where clinical care is delivered.
- Automation: Laboratory automation can be defined broadly as any device, software, or process that improves the efficiency of the laboratory.
- Integration: The act of integrating various automated tasks into a continuous process.

Market Overview

Healthcare Challenges among Growing Asian Economies help Create Growth Opportunities
The boom in economic growth among Asian countries is leading to considerable inequalities in healthcare provisions. In addition to the challenges of a rapidly increasing aged population, healthcare systems across the region are being confronted with the looming danger of infectious diseases As a result, there is an increasing need for fast and specific diagnosis and confirmation of diseases in order to control potential epidemics. This is paving the way for increased growth of the nucleic acid testing (NAT) markets in Asia. The threat of emerging infectious diseases such as avian flu and increasing disease burdens of HIV and tuberculosis are critical contributing factors to the growth opportunities in the NAT markets.
Conventional diagnostic methods such as cell culture, antibody testing, and even symptomatic diagnosis consume considerable time as compared to NAT. A polymerase chain reaction (PCR) test only takes 30 minutes to deliver results. It also requires minimal staff training and expertise due to its simple operations. Furthermore, data is verified with the included set of standards and a positive and negative control may also be further added. Constant improvements in technology have made NAT comparable to dip-sticks on the time front, thus making it a favored method of diagnosis, explains the analyst of this research service. In terms of sensitivity and specificity, NAT has a clear advantage over conventional immunoassay or serotyping, as it is not dependent on the operators personal judgment, and these inherent advantages are proving to be strong drivers for their increasing adoption throughout the region.

Increased Incidence and Prevalence of Infectious Disease Encourage the Adoption of NAT Technology
Since the severe acute respiratory syndrome (SARS) epidemic and the food poisoning due to Norovirus in January 2004, a lot of attention has been focused on NAT methods in Singapore. For example, during the dengue epidemic in 2005, the healthcare industry had resorted to using NAT with promising outcomes. The SARS epidemic also provided an entry point for the increased penetration of NAT technology into the markets in China and Hong Kong, where research projects are primarily focused on the study of infectious diseases using NAT. In Malaysia, viral and bacterial diseases are the key revenue drivers for the NAT market and dengue fever, tuberculosis, HIV, and viral hepatitis were the diseases with highest incidences in 2005.
Considering the limitation in funding as well as the transition time needed to fully adopt NAT into existing practices, the overall NAT market in Asia Pacific is likely to grow at a medium pace. Although initial adoption of the technology in the medical community has been slow, NAT is slowly but definitely becoming a recognized and preferred diagnostic tool, says the analyst. Additionally, an increase in research employing molecular biology related protocols is also driving the demand for more NAT-related technologies in Asia.










Table of contents:
 1. Research Overview

- 1. Research Overview

- - 1. Research Scope and Methodology

- - 2. Market Segmentation

- - 3. Glossary of Terms

- 2. Market Dynamics

- 1. Market Overview and Dynamics

- - 1. Overview of Nucleic Acid Testing Markets in Taiwan

- - 2. Market Drivers-- a. High Incidence and Prevalence of Infectious Diseases Promotes Increased Adoption of NAT Technologies-- b. Increase in Government-funded Initiatives for the Prevention of Infectious Diseases-- c. Increase in Funding for Local Life Science and Medical Research Increases the Use of NAT in Life Science Research-- d. Change in Disease Testing Profile from Diagnostic to Early Detection and Monitoring Increases the Application of NAT Technologies-- e. Comprehensive Health Insurance Coverage Increases Public Accessibility to NAT-- f. Limited Number of Local Suppliers and Import Orientated Medical Device Market Ensures Demand for Imported NAT Platforms

- - 3. Market Restraints-- a. Global Budget Scheme Limits Healthcare Expenditure-- b. High Price Limits Widespread Adoption of NAT Technology-- c. Strict Licensing and Product Registration Requirements Complicate Penetration of the Taiwanese Market-- d. Lack of Public Awareness of NAT Applications Leads to Low Demand for NAT-- e. Lack of Variety of Product Applications Leads to Reduced Use of NAT as a Diagnostic Technology

3. Current State of the Healthcare System in Taiwan

- 1. Disease Profile

- - 1. Infectious Diseases

- - 2. Non-communicable Diseases

- 2. Reimbursement Status

- - 1. Reimbursement for Medical Services

- 3. Regulatory Environment

- - 1. Medical Device Registration Requirements

- 4. Market Engineering Analysis

- 1. Market Analysis

- - 1. Market Engineering Measurements

- - 2. Market Age

- - 3. Revenue Forecasts

- - 4. Pricing Trends

- - 5. Future Trends

- 2. End-user Analysis

- - 1. End-user Analysis

- - 2. Testing Volumes

- 3. Distribution Structure

- - 1. Distribution Channel Analysis

- 4. Competitive Analysis

- - 1. Competitive Structure

- - 2. Market Share Analysis

- 5. Academic and Life Science Research

- 1. Academic and Life Science Research Overview

- - 1. Academic and Life Science Research in Taiwan

- 6. Conclusion

- 1. Strategic Recommendations for the Taiwanese Nucleic Acid Testing Market

- - 1. Strategic Recommendations

- 7. Frost & Sullivan Awards

- 1. Frost & Sullivan Awards for Nucleic Acid Testing Markets in Asia

- - 1. Customer Service Leadership Award

- - 2. Technology Innovation Award

- - 3. Vertical Market Penetration Leadership Award

- - 4. Competitive Strategy Leadership Award

- 8. Appendix

- 1. Appendix

- - 1. Molecular Diagnostics Tests Covered by the National Health Insurance Taiwan

- - 2. Caseloads of Notifiable Infectious Diseases in Taiwan--

- 3. Medical Device Classification in Taiwan

- - 4. Medical Device Categories in Taiwan

- - 5. Science and Technology Project Budgets in Taiwan

List Of Figures

Chapter 2

- Nucleic Acid Testing Markets: Market Drivers Ranked in Order of Impact (Taiwan), 2006-2010

- Nucleic Acid Testing Markets: Market Restraints Ranked in Order of Impact (Taiwan), 2006-2010

Chapter 3

- Nucleic Acid Testing Markets: Reported and Confirmed Cases of Notifiable Infectious Diseases (Taiwan), 2004

- Nucleic Acid Testing Markets: Major Causes of Death (Taiwan), 2004

Chapter 4

- Nucleic Acid Testing Markets: Revenue Forecasts (Taiwan), 2005-2010

- Nucleic Acid Testing Markets: Distribution Channels for Major Manufacturers of NAT Equipment (Taiwan), 2005

- Nucleic Acid Testing Markets: Distribution Channels for Manufacturers of NAT Kits/Reagents (Taiwan), 2005

Chapter 5

- Nucleic Acid Testing Markets: Funding Allocation for R&D under the National Science and Technology Development Plan (Taiwan), 2005-2008

- Nucleic Acid Testing Markets: List of Research and Diagnostic Activities Carried Out by the Center for Research and Diagnostics (Taiwan), 2004-2005

Chapter 8

- Nucleic Acid Testing Markets: Molecular Diagnostic Tests Covered by the National Health Insurance (Taiwan), 2005

- Nucleic Acid Testing Markets: Reported and Confirmed Cases of Notifiable Infectious Diseases (Taiwan), 2004

- Nucleic Acid Testing Markets: Medical Device Classification (Taiwan), 2005

- Nucleic Acid Testing Markets: Medical Device Categories in (Taiwan), 2005

- Nucleic Acid Testing Markets: Science and Technology Project Budgets in Individual Fields (Taiwan), 2003-2005




Order this report

  Company name:
  Contact person:
  Phone/fax:
  Email:
  Comments:
   


Product Trade Lead
0 leads found


Add New Buy/Sell Lead

© 2007-2010 MarketReportFinder.com